Posted by Michael Wonder on 19 Jan 2023
Synlogic receives rare paediatric disease designation from FDA for SYNB1934 for phenylketonuria
19 January 2023 - Synlogic today announced that SYNB1934 was granted rare paediatric disease designation by the US FDA for the potential treatment of phenylketonuria.
Synlogic’s pipeline includes its lead program in phenylketonuria, which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria, enteric hyperoxaluria and gout.
